FindTrial
Sign In

Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

Benfotiamine Prevents Vascular Dysfunction in Healthy Smokers

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00785460
Enrollment
20
Registered
2008-11-05
Start date
2008-01-31
Completion date
Unknown
Last updated
2008-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Brief summary

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation of the brachial artery.

Detailed description

Benfotiamine pretreatment (3 days)at high dosage (1050 mg/day) prevents in healthy subjects smoking-induced vascular dysfunction assessed by ultrasound flow mediated dilatation (FMD) of the brachial arteryand laboratory parameters (adhesion molecules).

Interventions

DRUGBenfotiamine

Sponsors

Ruhr University of Bochum
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy habitual smokers

Exclusion criteria

* any kind of chronic disease

Design outcomes

Primary

MeasureTime frame
Flow mediated dilatation3 days

Secondary

MeasureTime frame
Laboratory markers of endothelial function3 days

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026